Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of epcoritamab versus investigator's choice chemotherapy in relapsed or refractory diffuse large B-cell lymphoma
NL-OMON60392Phase 3Active, not recruiting
- Sponsor
- Genmab
- Start
- Jul 2021
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in diffuse large B-cell lymphoma (DLBCL), large-cell lymphoma, follicular lymphoma (FL) and 2 more comparing Epcoritamab with Investigator's choice standard of care (2 arms). Primary endpoints: Overall survival and Progression-free survival by independent review. Started Jul 2021; status: active, not recruiting.
02
Drugs
epcoritamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)large-cell lymphomafollicular lymphoma (FL)T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL)mature B-cell lymphoma
Beyond the preview
Go deeper on NL-OMON60392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60392.